SDZ 267489
Latest Information Update: 08 Dec 1997
At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 08 Dec 1997 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
- 29 Sep 1997 New profile